Evidence map›Paper›PMID 35458495›Full record

ArticleViruses2022

Early Emergence Phase of SARS-CoV-2 Delta Variant in Florida, US.

Eleonora Cella, Sobur Ali, Sarah E Schmedes, Brittany Rife Magalis, Simone Marini, Marco Salemi, Jason Blanton, Taj Azarian

Abstract read
In one paragraph

Article in Viruses, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. A high-throughput response to the SARS-CoV-2 pandemic.SLAS discovery : advancing life sciences R & D · 2024
    Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Eleonora CellaBurnett School of Biomedical Sciences, University of Central Florida, Orlando, FL 32827, USA.ORCID 0000-0002-7870-9744
Sobur AliBurnett School of Biomedical Sciences, University of Central Florida, Orlando, FL 32827, USA.ORCID 0000-0002-0376-8803
Sarah E SchmedesBureau of Public Health Laboratories, Florida Department of Health, Jacksonville, FL 32202, USA.
Brittany Rife MagalisEmerging Pathogens Institute, University of Florida, Gainesville, FL 32608, USA.
Simone MariniDepartment of Epidemiology, University of Florida, Gainesville, FL 32608, USA.
Marco SalemiEmerging Pathogens Institute, University of Florida, Gainesville, FL 32608, USA.
Jason BlantonBureau of Public Health Laboratories, Florida Department of Health, Jacksonville, FL 32202, USA.
Taj AzarianBurnett School of Biomedical Sciences, University of Central Florida, Orlando, FL 32827, USA.ORCID 0000-0002-8611-5241

Funding

CDC HHS
6 · The paper itself

Abstract

SARS-CoV-2, the causative agent of COVID-19, emerged in late 2019. The highly contagious B.1.617.2 (Delta) variant of concern (VOC) was first identified in October 2020 in India and subsequently disseminated worldwide, later becoming the dominant lineage in the US. Understanding the local transmission dynamics of early SARS-CoV-2 introductions may inform actionable mitigation efforts during subsequent pandemic waves. Yet, despite considerable genomic analysis of SARS-CoV-2 in the US, several gaps remain. Here, we explore the early emergence of the Delta variant in Florida, US using phylogenetic analysis of representative Florida and globally sampled genomes. We find multiple independent introductions into Florida primarily from North America and Europe, with a minority originating from Asia. These introductions led to three distinct clades that demonstrated varying relative rates of transmission and possessed five distinct substitutions that were 3-21 times more prevalent in the Florida sample as compared to the global sample. Our results underscore the benefits of routine viral genomic surveillance to monitor epidemic spread and support the need for more comprehensive genomic epidemiology studies of emerging variants. In addition, we provide a model of epidemic spread of newly emerging VOCs that can inform future public health responses.

Indexed as

COVID-19SARS-CoV-2FloridaHumansMutationPhylogenyDeltaearly emergenceFloridaphylogenetic analysisSARS-CoV-2

Identifiers

PMID35458495
PMCPMC9028683

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.